Inventage Lab

Inventage Lab Change in Working Capital

The Change in Working Capital of Inventage Lab (389470.KQ) as of Oct 24, 2026 is -2.10 B KRW. In the previous year, Change in Working Capital was 168.78 M KRW — a change of -1,343.01% (lower).

Change in Working Capital

-2.10 BKRW

YoY

-1,343.01%

Last updated:

Change in Working Capital of Inventage Lab is 2025 -2.10 B KRW. Change in Working Capital of Inventage Lab was 2024 168.78 M KRW. It decreases by -1,343.01% lower compared to the previous year.

The Inventage Lab Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2019
242.46 M KRW
Jan 1, 2020
-85.98 M KRW
Jan 1, 2021
-2.00 B KRW
Jan 1, 2022
1.78 B KRW
Jan 1, 2023
371.05 M KRW
Jan 1, 2024
168.78 M KRW
Jan 1, 2025
-2.10 B KRW
The Inventage Lab Change in Working Capital history
YEARChange in Working CapitalYoY
-2.10 BKRW-1,343.01%
168.78 MKRW-54.51%
371.05 MKRW-79.18%
1.78 BKRW-189.03%
-2.00 BKRW+2,228.12%
-85.98 MKRW-135.46%
242.46 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

Change in Working Capital of Inventage Lab is -2.10 B KRW in 2025.

Change in Working Capital of Inventage Lab changed from 168.78 M KRW to -2.10 B KRW, representing a -1,343.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Inventage Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Inventage Lab

All Key Metrics — Inventage Lab